Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Increases By 14.8%

HilleVax, Inc. (NASDAQ:HLVX) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 1,550,000 shares, a growth of 14.8% from the May 31st total of 1,350,000 shares. Based on an average trading volume of 177,600 shares, the short-interest ratio is currently 8.7 days. Approximately 9.3% of the company’s stock are short sold.

Insider Activity

In other news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $14.44, for a total transaction of $86,640.00. Following the completion of the sale, the director now directly owns 789,776 shares in the company, valued at $11,404,365.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of HilleVax stock in a transaction dated Thursday, April 4th. The shares were acquired at an average price of $14.50 per share, with a total value of $128,325.00. Following the completion of the transaction, the insider now owns 8,544,187 shares of the company’s stock, valued at approximately $123,890,711.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Aditya Kohli sold 6,000 shares of the stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $14.44, for a total transaction of $86,640.00. Following the transaction, the director now directly owns 789,776 shares in the company, valued at approximately $11,404,365.44. The disclosure for this sale can be found here. Insiders sold 18,898 shares of company stock worth $280,406 over the last ninety days. Corporate insiders own 71.10% of the company’s stock.

Institutional Investors Weigh In On HilleVax

A number of hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. raised its holdings in shares of HilleVax by 4.1% during the fourth quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after buying an additional 71,938 shares during the last quarter. Catalys Pacific LLC bought a new stake in shares of HilleVax during the fourth quarter valued at approximately $21,009,000. Acuta Capital Partners LLC raised its holdings in shares of HilleVax by 328.5% during the third quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock valued at $3,636,000 after buying an additional 207,241 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of HilleVax during the third quarter valued at approximately $2,374,000. Finally, Swiss National Bank raised its holdings in shares of HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares during the last quarter. Institutional investors own 86.42% of the company’s stock.

HilleVax Price Performance

NASDAQ HLVX traded down $0.24 during trading hours on Wednesday, reaching $14.04. The company’s stock had a trading volume of 2,574 shares, compared to its average volume of 160,441. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.92 and a current ratio of 10.92. The business has a 50-day simple moving average of $13.65 and a 200 day simple moving average of $14.89. HilleVax has a 52 week low of $9.94 and a 52 week high of $20.22.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). As a group, equities research analysts expect that HilleVax will post -3.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of HilleVax in a research report on Friday, May 10th. JPMorgan Chase & Co. increased their price target on shares of HilleVax from $21.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 15th.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.